A detailed history of Fortis Capital Advisors, LLC transactions in Repligen Corp stock. As of the latest transaction made, Fortis Capital Advisors, LLC holds 1,782 shares of RGEN stock, worth $213,982. This represents 0.14% of its overall portfolio holdings.

Number of Shares
1,782
Holding current value
$213,982
% of portfolio
0.14%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

BUY
$170.78 - $208.42 $304,329 - $371,404
1,782 New
1,782 $328 Million
Q1 2023

May 15, 2023

BUY
$154.26 - $198.1 $10,335 - $13,272
67 Added 32.68%
272 $45.8 Million
Q4 2022

Feb 14, 2023

BUY
$162.42 - $220.56 $33,296 - $45,214
205 New
205 $34.7 Million

Others Institutions Holding RGEN

About REPLIGEN CORP


  • Ticker RGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 55,491,200
  • Market Cap $6.66B
  • Description
  • Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....
More about RGEN
Track This Portfolio

Track Fortis Capital Advisors, LLC Portfolio

Follow Fortis Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fortis Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fortis Capital Advisors, LLC with notifications on news.